Patents by Inventor Frédéric Gilbert Labéguère

Frédéric Gilbert Labéguère has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144823
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, R3a, R3b, Het, X and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of endocrine, nutritional, metabolic, and/or cardiovascular diseases by administering the compound of the invention.
    Type: Application
    Filed: February 17, 2020
    Publication date: May 12, 2022
    Inventors: Stéphane Nicolas Alain BEAUMONT, Xavier Marie BOCK, Daniel COMAS MARTINEZ, Agnès Marie JONCOUR, Frédéric Gilbert LABÉGUÈRE, Miriam LÓPEZ RAMOS, Taoues TEMAL-LAÏB
  • Patent number: 11220499
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 11, 2022
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
  • Patent number: 10829478
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: November 10, 2020
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Patent number: 10550100
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: February 4, 2020
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Rama Heng, Frédéric André De Ceuninck, Luke Jonathan Alvey, David Amantini, Franck Laurent Brebion, Pierre Marc Marie Joseph Deprez, Romain Luc Marie Gosmini, Hélène Marie Jary, Christophe Peixoto, Iuliana Ecaterina Pop-Botez, Marie Laurence Claire Varin
  • Patent number: 10508111
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting IRAK family kinases, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases and/or proliferative diseases by administering the compound of the invention.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: December 17, 2019
    Assignee: GALAPAGOS NV
    Inventors: Reginald Christophe Xavier Brys, Raphaël Jean Joël Geney, Agnès Marie Joncour, Julien Georges Pierre-Olivier Doyon, Frédéric Gilbert Labéguère, Jean-Michel Lefrançois, Oscar Mammoliti, Benoît Antoine Schmitt, Steven Emiel Van Der Plas, Christel Jeanne Marie Menet
  • Publication number: 20190315719
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6a, R6b, the subscript n and Cy are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Application
    Filed: June 1, 2017
    Publication date: October 17, 2019
    Inventors: Frédéric Gilbert LABÉGUÈRE, Rama HENG, Frédéric André DE CEUNINCK, Luke Jonathan ALVEY, David AMANTINI, Franck Laurent BREBION, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
  • Publication number: 20190300503
    Abstract: The present invention discloses compounds according to Formula I: Wherein R1, R2, R3a, R3b, R6, Cy, and the subscript n are as defined herein. The present invention relates to compounds inhibiting ADAMTS, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, and/or diseases involving degradation of cartilage and/or disruption of cartilage homeostasis by administering the compound of the invention.
    Type: Application
    Filed: June 1, 2017
    Publication date: October 3, 2019
    Inventors: Frédéric Gilbert LABÉGUÈRE, Rama HENG, Frédéric André DE CEUNINCK, Luke Jonathan ALVEY, David AMANTINI, Franck Laurent BREBION, Pierre Marc Marie Joseph DEPREZ, Romain Luc Marie GOSMINI, Hélène Marie JARY, Christophe PEIXOTO, Iuliana Ecaterina POP-BOTEZ, Marie Laurence Claire VARIN
  • Publication number: 20190002458
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Application
    Filed: May 4, 2018
    Publication date: January 3, 2019
    Applicant: GALAPAGOS NV
    Inventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
  • Publication number: 20180305351
    Abstract: The present invention discloses compounds according to Formula I: wherein R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting IRAK family kinases, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of inflammatory diseases, autoimmune diseases and/or proliferative diseases by administering the compound of the invention.
    Type: Application
    Filed: October 14, 2016
    Publication date: October 25, 2018
    Inventors: Reginald Christophe Xavier BRYS, Raphaël Jean Joël GENEY, Agnès Marie JONCOUR, Julien Georges Pierre-Olivier DOYON, Frédéric Gilbert LABÉGUÈRE, Jean-Michel LEFRANÇOIS, Oscar MAMMOLITI, Benoît Antoine SCHMITT, Steven Emiel VAN DER PLAS, Christel Jeanne Marie MENET
  • Patent number: 10047083
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: August 14, 2018
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
  • Publication number: 20180016275
    Abstract: A compound according to Formula Ia: wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Application
    Filed: May 30, 2017
    Publication date: January 18, 2018
    Applicant: GALAPAGOS NV
    Inventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
  • Patent number: 9708312
    Abstract: A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: July 18, 2017
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
  • Publication number: 20160244442
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Application
    Filed: December 11, 2015
    Publication date: August 25, 2016
    Applicant: GALAPAGOS NV
    Inventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
  • Publication number: 20160039807
    Abstract: A compound according to Formula (Ia), wherein Cy, L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula (I) that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis), lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Application
    Filed: December 17, 2013
    Publication date: February 11, 2016
    Applicant: GALAPAGOS NV
    Inventors: Frédéric Gilbert LABÉGUÈRE, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice SANIÈRE, Stephen Robert FLETCHER
  • Patent number: 9255095
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: February 9, 2016
    Assignee: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Sanière, Stephen Robert Fletcher
  • Patent number: 8927543
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: January 6, 2015
    Assignee: Galapagos NV
    Inventors: Frédéric Gilbert Labéguére, Gregory John Robert Newsome, Luke Jonathan Alvey, Laurent Raymond Maurice Saniére, Stephen Robert Fletcher
  • Publication number: 20140121204
    Abstract: A compound according to Formula Ia: wherein L1, G, and R1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.
    Type: Application
    Filed: January 6, 2014
    Publication date: May 1, 2014
    Applicant: GALAPAGOS NV
    Inventors: Frédéric Gilbert Labéguère, Gregory John Robert NEWSOME, Luke Jonathan ALVEY, Laurent Raymond Maurice Sanière, Stephen Robert FLETCHER